Results 91 to 100 of about 9,672 (236)

Era of direct acting antivirals in chronic hepatitis C: Who will benefit? [PDF]

, 2015
published_or_final_versio
Fung, JYY
core   +1 more source

Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT This multicentre study investigated the dynamics of thrombospondin 2 (TSP2) levels during direct‐acting antiviral (DAA) therapy in hepatitis C virus (HCV) infected patients and evaluated TSP2's potential as a predictive marker for hepatocellular carcinoma (HCC).
Takanobu Iwadare, Takefumi Kimura, Ayumi Sugiura, Taiki Okumura, Shun‐ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Tomoo Yamazaki, Satoru Joshita, Naoki Tanaka, Takeji Umemura   +10 more
wiley   +1 more source

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada

Canadian Journal of Gastroenterology and Hepatology, 2015
BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to ...
Sergio M Borgia, Adenike Rowaiye
doaj   +1 more source

Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT Chronic hepatitis C virus (HCV) infection can be associated with neuropsychiatric symptoms like fatigue and cognitive impairment, independent of the liver status. The present study aims to assess changes in the pattern and extent of neuropsychological symptoms after successful treatment with interferon (IFN)‐based and IFN‐free therapy.
Meike Dirks, Ann‐Katrin Hennemann, Gerrit M. Grosse, Anika Beer, Henning Pflugrad, Kim Haag, Ramona Schuppner, Katja Deterding, Markus Cornberg, Heiner Wedemeyer, Karin Weissenborn   +10 more
wiley   +1 more source

A hepatitis C-vírus-bázispolimorfizmus jelentősége a kezelésben [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelése az elmúlt huszonöt évben igen jelentős fejlődésen ment keresztül.
Tornai, István
core   +1 more source

Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study

Liver International, Volume 45, Issue 4, April 2025.
ABSTRACT Background & Aims Glecaprevir/Pibrentasvir (GLE/PIB) has been approved by the European Medicine Agency (EMA) and by the US Food and Drug Administration (US‐FDA) for the treatment of children and adolescents from 3 years of age with chronic hepatitis C virus (CHC) infection.
Mariangela Stinco, Chiara Rubino, Elisa Bartolini, Federica Nuti, Giulia Paolella, Gabriella Nebbia, Erika Silvestro, Silvia Garazzino, Emanuele Nicastro, Lorenzo D'Antiga, Chiara Zanchi, Laura Morra, Raffaele Iorio, Fabiola Di Dato, Giuseppe Maggiore, Maria Rita Sartorelli, Donatella Comparcola, Marta Stracuzzi, Vania Giacomet, Francesca Musto, Michele Pinon, Pierluigi Calvo, Ines Carloni, Federica Zallocco, Mara Cananzi, Sandra Trapani, Giuseppe Indolfi   +26 more
wiley   +1 more source

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Annals of Hepatology, 2017
Introduction: Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival.
Eric M. Yoshida, Paul Kwo, Kosh Agarwal, Christophe Duvoux, François Durand, Markus Peck-Radosavljevic, Leslie Lilly, Bernard Willems, Hugo Vargas, Princy Kumar, Robert S. Brown Jr., Yves Horsmans, Shampa De-Oertel, Sarah Arterburn, Hadas Dvory-Sobol, Diana M. Brainard, John G. McHutchison, Norah Terrault, Mario Rizzetto, Beat Müllhaupt   +19 more
doaj   +1 more source

NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus:Prevalence and Effect on Treatment Outcome [PDF]

, 2017
Background & Aims The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs).
Brainard, Diana M, Chuang, Wan-Long, Doehle, Brian, Dore, Gregory J, Dvory-Sobol, Hadas, Han, Kwang-Hyub, Hedskog, Charlotte, Jacobson, Ira, Knox, Steven, Mangia, Alessandra, Martin, Ross, McHutchison, John G, Miller, Michael D., Mizokami, Masashi, Mo, Hongmei, Pianko, Stephen, Sulkowski, Mark, Svarovskaia, Evguenia, Yun, Chohee, Zeuzem, Stefan   +19 more
core   +2 more sources

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

ClinicoEconomics and Outcomes Research, 2018
Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the ...
Heath K
doaj  

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients [PDF]

, 2017
Short communication[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and ...
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Meijide, Héctor, Mena, Álvaro, Morano, Luis, Pedreira, José D., Pernas, Berta, Poveda, Eva, Rodríguez-Osorio, Iria, Suárez, Marta, Tabernilla, Andrés   +12 more
core   +2 more sources